Your browser doesn't support javascript.
loading
Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial.
Guttman-Yassky, E; Bahadori, L; Brooks, L; Clark, K L; Grindebacke, H; Ho, C N; Katial, R; Pham, T-H; Walton, C; Datto, C J.
Afiliação
  • Guttman-Yassky E; Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Bahadori L; Late Stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Brooks L; Late Stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Clark KL; Late Stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Grindebacke H; Late Stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Ho CN; Patient Centered Science, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA.
  • Katial R; BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA.
  • Pham TH; National Jewish Health, Denver, Colorado, USA.
  • Walton C; Translational Science and Experimental Medicine, Early Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Datto CJ; Late Stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
J Eur Acad Dermatol Venereol ; 37(10): e1211-e1214, 2023 10.
Article em En | MEDLINE | ID: mdl-37178404

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Dermatite Atópica Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Dermatite Atópica Idioma: En Ano de publicação: 2023 Tipo de documento: Article